{"id":3543,"date":"2021-08-27T08:59:00","date_gmt":"2021-08-27T15:59:00","guid":{"rendered":"https:\/\/allocare.caredx.com\/?p=3543"},"modified":"2022-08-16T14:13:38","modified_gmt":"2022-08-16T21:13:38","slug":"fda-oks-new-drug-for-ckd-related-pruritus","status":"publish","type":"post","link":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2021\/08\/27\/fda-oks-new-drug-for-ckd-related-pruritus\/","title":{"rendered":"FDA OKs New Drug for CKD-Related Pruritus"},"content":{"rendered":"<span class=\"simplefavorite-button has-count loading\" data-postid=\"3543\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"3\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>\n<p>&#8220;The FDA approved difelikefalin (Korsuva) on Monday for treating pruritus in chronic kidney disease (CKD) patients,\u00a0Cara Therapeutics and Vifor Pharma announced.<\/p>\n\n\n\n<p>Difelikefalin is a first-in-class kappa opioid receptor (KOR) agonist that targets the peripheral nervous system, according to the two companies. Administered as an injection (0.5 \u03bcg\/kg three times per week), the drug is indicated for moderate-to-severe pruritus in CKD patients on hemodialysis &#8212; the first therapy approved in this setting.&#8221;<\/p>\n\n\n\n<p>Read more, <a href=\"https:\/\/www.medpagetoday.com\/nephrology\/esrd\/94182?xid=nl_covidupdate_2021-08-25&amp;eun=g1917319d0r&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=DailyUpdate_082521&amp;utm_term=NL_Gen_Int_Daily_News_Update_active\">here<\/a>.<\/p>\n<span class=\"simplefavorite-button has-count loading\" data-postid=\"3543\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"3\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>","protected":false},"excerpt":{"rendered":"<p>Loading &#8220;The FDA approved difelikefalin (Korsuva) on Monday for treating pruritus in chronic kidney disease (CKD) patients,\u00a0Cara Therapeutics and Vifor Pharma announced. Difelikefalin is a first-in-class kappa opioid receptor (KOR) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2021\/08\/27\/fda-oks-new-drug-for-ckd-related-pruritus\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FDA OKs New Drug for CKD-Related Pruritus&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":3338,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":0,"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","_ecp_custom_2":"","footnotes":""},"categories":[45,912],"tags":[44,209,208],"post_format":[],"Dislikes":"","Likes":"","simplefavorites_count":"3","views":"1312","post_likes_plusCounter":"1","post_dislikes_plusCounter":"","acf":[],"_links":{"self":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/3543"}],"collection":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/comments?post=3543"}],"version-history":[{"count":1,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/3543\/revisions"}],"predecessor-version":[{"id":3544,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/3543\/revisions\/3544"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media\/3338"}],"wp:attachment":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media?parent=3543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/categories?post=3543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/tags?post=3543"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/post_format?post=3543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}